Oatly Group AB - ADR vs uniQure N.V. Ordinary Shares — how do they compare? Oatly Group AB - ADR trades at $11.1 (market cap $355.50M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 4.1× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| OTLY | QURE | |
|---|---|---|
Market Cap | $355.50M | $1.45B |
Volume | 70,853 | 3,323,243 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $70.59 |
52-Week Low | $8.03 | $9.03 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $859.91M | $707.46M |
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.88, up 1.97% today, with a bearish technical signal despite a neutral RSI. Revenue grew to $862M in 2025, but net losses persist at -$153M. The company shows improving margins and raised its 2026 revenue outlook after Q2 results. Analyst consensus is mixed with a $12.28 price target, indicating modest upside potential.
The outlook hinges on OTLY's path to profitability amid high debt and negative cash flows. While product innovation and distribution gains offer growth catalysts, the stock faces risks from sustained losses and competitive pressures. Investors should weigh the turnaround progress against financial stability concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →